{"success":true,"data":{"pressRelease":{"id":"91875","rtpr_id":"nGNX8CXCj1","ticker":"CYTK","exchange":"NASDAQ","all_tickers":["CYTK"],"title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-07-17T20:00:00.105Z","article_body":"SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,\nIncorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted\nstock options to purchase an aggregate of 21,220 shares of common stock and\n14,067 restricted stock units (RSUs) that will be settled in shares of common\nstock upon vesting to 10 employees, whose employment commenced in June and\nJuly 2026 as a material inducement to their employment.\n\nThe RSUs will vest over 3 years, with 40% of the RSUs vesting on the first\nanniversary of the applicable grant date, an additional 40% of the RSUs\nvesting on the second anniversary of the grant date and the final 20% vesting\non the third anniversary of the grant date, in each case, subject to each\nrespective employee’s continued service with the Company. The stock options\nthat were granted are subject to an exercise price of $82.62 per share, which\nis equal to the closing price of the Company’s common stock on July 15, 2026\nand will vest over 4 years, with 1/4(th) of the shares underlying the\nemployee’s option vesting on the one-year anniversary of the grant date and\nthe remaining shares thereafter vesting in monthly installments at a rate of\n1/48(th) of the shares underlying such stock options over the subsequent 36\nmonths, subject to each respective employee’s continued service with the\nCompany. The stock options have a 10-year term. These awards are subject to\nthe terms and conditions of the Company's Amended and Restated 2004 Equity\nIncentive Plan and the applicable award agreements pursuant to which the\nawards were granted.\n\nThe stock options and RSUs were granted as material inducements to employment\nin accordance with Nasdaq Listing Rule 5635(c)(4).\n\nAbout Cytokinetics\n\nCytokinetics is a specialty cardiovascular biopharmaceutical company, building\non its over 25 years of pioneering scientific innovations in muscle biology,\nand advancing a pipeline of potential new medicines for patients suffering\nfrom diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO(®)\n(aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and\nChina for the treatment of adults with symptomatic obstructive hypertrophic\ncardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a\nPhase 3 clinical trial of aficamten in patients with non-obstructive HCM\n(nHCM), the company plans to discuss the results with the U.S. FDA and other\nregulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an\ninvestigational cardiac myosin activator for the potential treatment of\npatients with heart failure with severely reduced ejection fraction and\nulacamten, an investigational cardiac myosin inhibitor for the potential\ntreatment of heart failure with preserved ejection fraction, while continuing\npre-clinical research and development in muscle biology.\n\nFor additional information about Cytokinetics, visit www.cytokinetics.com and\nfollow us on X\n(https://www.globenewswire.com/Tracker?data=2z_E7s6vPanHvGzVZX9I6gJivtmdAtiKMPL7J7RRSiQnqShXt34SfANFCm1bL6fEAg90DV_5SPHtpAWCA31eYA==),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=fIqOcMXDwL7-FD6Wl75UJkYVR3e0Q33QL4g_mwmu6kC6eAhI6o2pu_g9OoUhUtFgJhrN_S_rywmcynDxa-rxTtfL9LUrqHZwxKTj1MJAE3LiRZ-0l8h17NutMUF5oruS),\nFacebook\n(https://www.globenewswire.com/Tracker?data=kr-oasnlT-k_YI7r2ZJ2ekWtOLQSEfuXzhuLzese_pQW7JnDKTDL3dCp7i2aODk0Tcyf5LfkNpwqu3EAF3_vBvF3ysxdukH9Avok6HgSy0E=)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=al1Sh_m5GclJPhT-rkFvq0_NZCnEFX95fKw8P_MJT0rU9GcsgECG_-oPz4jEKsaDYK9MU3bCXLtrfmV_Dq1ZDbg8Q79IWqZsVxiftdJqxWZB9Cvc7VAZ83aKkgrazruA).\n\nDisclaimer \n\nOmecamtiv mecarbil and ulacamten are investigational medicines. They have not\nbeen approved nor determined to be safe or efficacious for any disease state\nor any indication by FDA or any other regulatory agency.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements for purposes of the\nPrivate Securities Litigation Reform Act of 1995 (the \"Act\"). Cytokinetics\ndisclaims any intent or obligation to update these forward-looking statements\nand claims the protection of the Act's Safe Harbor for forward-looking\nstatements. Examples of such statements include, but are not limited to,\nstatements relating to Cytokinetics' and its partners' research and\ndevelopment activities of Cytokinetics’ product candidates. Such statements\nare based on management's current expectations, but actual results may differ\nmaterially due to various risks and uncertainties, including, but not limited\nto the risks related to Cytokinetics' business outlined in Cytokinetics'\nfilings with the Securities and Exchange Commission particularly under the\ncaption “Risk Factors” in Cytokinetics’ latest Annual Report on Form\n10-K. Forward-looking statements are not guarantees of future performance, and\nCytokinetics' actual results of operations, financial condition and liquidity,\nand the development of the industry in which it operates, may differ\nmaterially from the forward-looking statements contained in this press\nrelease. Any forward-looking statements that Cytokinetics makes in this press\nrelease speak only as of the date of this press release. Cytokinetics assumes\nno obligation to update its forward-looking statements whether as a result of\nnew information, future events or otherwise, after the date of this press\nrelease.\n\nCYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of\nCytokinetics in the U.S. and certain other countries.\n\nMYQORZO(®) is a registered trademark of Cytokinetics in the U.S. and the\nEuropean Union.\n\nContact:\nCytokinetics \nDiane Weiser\nSenior Vice President, Corporate Affairs\n(415) 290-7757\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/52e2be9f-e9e3-43af-a747-123fdcac4253)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8CXCj1","title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"CYTK","created":"2026-07-17T20:00:00.105Z","tickers":["CYTK"],"exchange":"NASDAQ","article_body":"SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,\nIncorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted\nstock options to purchase an aggregate of 21,220 shares of common stock and\n14,067 restricted stock units (RSUs) that will be settled in shares of common\nstock upon vesting to 10 employees, whose employment commenced in June and\nJuly 2026 as a material inducement to their employment.\n\nThe RSUs will vest over 3 years, with 40% of the RSUs vesting on the first\nanniversary of the applicable grant date, an additional 40% of the RSUs\nvesting on the second anniversary of the grant date and the final 20% vesting\non the third anniversary of the grant date, in each case, subject to each\nrespective employee’s continued service with the Company. The stock options\nthat were granted are subject to an exercise price of $82.62 per share, which\nis equal to the closing price of the Company’s common stock on July 15, 2026\nand will vest over 4 years, with 1/4(th) of the shares underlying the\nemployee’s option vesting on the one-year anniversary of the grant date and\nthe remaining shares thereafter vesting in monthly installments at a rate of\n1/48(th) of the shares underlying such stock options over the subsequent 36\nmonths, subject to each respective employee’s continued service with the\nCompany. The stock options have a 10-year term. These awards are subject to\nthe terms and conditions of the Company's Amended and Restated 2004 Equity\nIncentive Plan and the applicable award agreements pursuant to which the\nawards were granted.\n\nThe stock options and RSUs were granted as material inducements to employment\nin accordance with Nasdaq Listing Rule 5635(c)(4).\n\nAbout Cytokinetics\n\nCytokinetics is a specialty cardiovascular biopharmaceutical company, building\non its over 25 years of pioneering scientific innovations in muscle biology,\nand advancing a pipeline of potential new medicines for patients suffering\nfrom diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO(®)\n(aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and\nChina for the treatment of adults with symptomatic obstructive hypertrophic\ncardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a\nPhase 3 clinical trial of aficamten in patients with non-obstructive HCM\n(nHCM), the company plans to discuss the results with the U.S. FDA and other\nregulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an\ninvestigational cardiac myosin activator for the potential treatment of\npatients with heart failure with severely reduced ejection fraction and\nulacamten, an investigational cardiac myosin inhibitor for the potential\ntreatment of heart failure with preserved ejection fraction, while continuing\npre-clinical research and development in muscle biology.\n\nFor additional information about Cytokinetics, visit www.cytokinetics.com and\nfollow us on X\n(https://www.globenewswire.com/Tracker?data=2z_E7s6vPanHvGzVZX9I6gJivtmdAtiKMPL7J7RRSiQnqShXt34SfANFCm1bL6fEAg90DV_5SPHtpAWCA31eYA==),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=fIqOcMXDwL7-FD6Wl75UJkYVR3e0Q33QL4g_mwmu6kC6eAhI6o2pu_g9OoUhUtFgJhrN_S_rywmcynDxa-rxTtfL9LUrqHZwxKTj1MJAE3LiRZ-0l8h17NutMUF5oruS),\nFacebook\n(https://www.globenewswire.com/Tracker?data=kr-oasnlT-k_YI7r2ZJ2ekWtOLQSEfuXzhuLzese_pQW7JnDKTDL3dCp7i2aODk0Tcyf5LfkNpwqu3EAF3_vBvF3ysxdukH9Avok6HgSy0E=)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=al1Sh_m5GclJPhT-rkFvq0_NZCnEFX95fKw8P_MJT0rU9GcsgECG_-oPz4jEKsaDYK9MU3bCXLtrfmV_Dq1ZDbg8Q79IWqZsVxiftdJqxWZB9Cvc7VAZ83aKkgrazruA).\n\nDisclaimer \n\nOmecamtiv mecarbil and ulacamten are investigational medicines. They have not\nbeen approved nor determined to be safe or efficacious for any disease state\nor any indication by FDA or any other regulatory agency.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements for purposes of the\nPrivate Securities Litigation Reform Act of 1995 (the \"Act\"). Cytokinetics\ndisclaims any intent or obligation to update these forward-looking statements\nand claims the protection of the Act's Safe Harbor for forward-looking\nstatements. Examples of such statements include, but are not limited to,\nstatements relating to Cytokinetics' and its partners' research and\ndevelopment activities of Cytokinetics’ product candidates. Such statements\nare based on management's current expectations, but actual results may differ\nmaterially due to various risks and uncertainties, including, but not limited\nto the risks related to Cytokinetics' business outlined in Cytokinetics'\nfilings with the Securities and Exchange Commission particularly under the\ncaption “Risk Factors” in Cytokinetics’ latest Annual Report on Form\n10-K. Forward-looking statements are not guarantees of future performance, and\nCytokinetics' actual results of operations, financial condition and liquidity,\nand the development of the industry in which it operates, may differ\nmaterially from the forward-looking statements contained in this press\nrelease. Any forward-looking statements that Cytokinetics makes in this press\nrelease speak only as of the date of this press release. Cytokinetics assumes\nno obligation to update its forward-looking statements whether as a result of\nnew information, future events or otherwise, after the date of this press\nrelease.\n\nCYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of\nCytokinetics in the U.S. and certain other countries.\n\nMYQORZO(®) is a registered trademark of Cytokinetics in the U.S. and the\nEuropean Union.\n\nContact:\nCytokinetics \nDiane Weiser\nSenior Vice President, Corporate Affairs\n(415) 290-7757\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/52e2be9f-e9e3-43af-a747-123fdcac4253)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-17T20:00:00.161322666Z","server_sent_at_ms":1784318400161},"received_at":"2026-07-17T20:00:00.227Z","source_url":"https://www.globenewswire.com/news-release/2026/07/17/3329267/35409/en/Cytokinetics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html"},"analysis":{"id":"80939","press_release_id":"91875","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Cytokinetics granted inducement awards consisting of 21,220 stock options and 14,067 restricted stock units to 10 new employees hired in June and July 2026.\n\nThe stock options have an exercise price of $82.62 per share, equal to the closing price on July 15, 2026, and vest over four years. The RSUs vest over three years on a 40/40/20 schedule.\n\nThese awards were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant disclosure."},"keyFigures":{"customDimensions":{"rsus_granted":14067,"exercise_price":82.62,"new_hires_count":10,"options_granted":21220,"rsu_vesting_years":3,"option_vesting_years":4}},"quotedText":"","namedEntities":{"people":[{"name":"Diane Weiser","role":"Senior Vice President, Corporate Affairs"}],"products":["MYQORZO","aficamten","omecamtiv mecarbil","ulacamten"],"companies":[{"name":"Cytokinetics","ticker":"CYTK"},{"name":"Nasdaq"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$82.62","context":"stock option exercise price"}]},"materialImpact":{"score":1,"reasoning":"Routine Form 8-K item disclosing inducement grants to 10 new employees. The aggregate number of shares (21,220 options and 14,067 RSUs) is immaterial relative to the company's market cap and represents standard administrative procedure for hiring."},"tickerRelevance":{"others":[],"primary":"CYTK"},"globalImportance":5,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid_cap_biotech","eventGravity":"routine_inducement_grant"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Cytokinetics granted inducement awards consisting of 21,220 stock options and 14,067 restricted stock units to 10 new employees hired in June and July 2026.\n\nThe stock options have an exercise price of $82.62 per share, equal to the closing price on July 15, 2026, and vest over four years. The RSUs vest over three years on a 40/40/20 schedule.\n\nThese awards were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).","key_figures":{"customDimensions":{"rsus_granted":14067,"exercise_price":82.62,"new_hires_count":10,"options_granted":21220,"rsu_vesting_years":3,"option_vesting_years":4}},"named_entities":{"people":[{"name":"Diane Weiser","role":"Senior Vice President, Corporate Affairs"}],"products":["MYQORZO","aficamten","omecamtiv mecarbil","ulacamten"],"companies":[{"name":"Cytokinetics","ticker":"CYTK"},{"name":"Nasdaq"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$82.62","context":"stock option exercise price"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-17T20:09:24.830Z","global_importance":5,"audience_relevance":15,"importance_components":{"tickerTier":"mid_cap_biotech","eventGravity":"routine_inducement_grant"}},"durationMs":96946,"modelName":"glm-4.7"}}